Arcturus Therapeutics Holdings (ARCT) Short term Debt (2020 - 2022)

Arcturus Therapeutics Holdings' Short term Debt history runs 3 years deep, the most recent figure standing at $60.7 million for Q4 2022.

• Quarterly Short term Debt rose 169.89% year-over-year to $60.7 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $60.7 million (up 169.89% YoY) and the FY2022 annual result came in at $60.7 million, up 169.89% from the prior year.
• Short term Debt was $60.7 million for Q4 2022 at Arcturus Therapeutics Holdings, up from $27.7 million in the prior quarter.
• Across five years, Short term Debt topped out at $60.7 million in Q4 2022 and bottomed at $1.2 million in Q4 2020.
• A 3-year average of $21.1 million and a median of $22.5 million in 2021 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2021 — Short term Debt jumped 1697.92% — and 2022, when it surged 49.89%.
• Arcturus Therapeutics Holdings' Short term Debt stood at $1.2 million in 2020, then soared by 1697.92% to $22.5 million in 2021, then soared by 169.89% to $60.7 million in 2022.
• Business Quant data shows ARCT's Short term Debt at $60.7 million in Q4 2022, $27.7 million in Q3 2022, and $27.0 million in Q2 2022.